Dr. Joseph A. Miccio
Claim this profilePenn State Milton S Hershey Medical Center
Studies Prostate Adenocarcinoma
Studies Prostate Cancer
9 reported clinical trials
29 drugs studied
Affiliated Hospitals
Clinical Trials Joseph A. Miccio is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Relugolix + Radiation
for Advanced-Stage Prostate Cancer
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Recruiting0 awards Phase 2
More about Joseph A. Miccio
Clinical Trial Related4 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Joseph A. Miccio has experience with
- Apalutamide
- Stereotactic Body Radiation Therapy
- Relugolix
- Degarelix
- Radiation Therapy
- Triptorelin
Breakdown of trials Joseph A. Miccio has run
Prostate Adenocarcinoma
Prostate Cancer
Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph A. Miccio specialize in?
Joseph A. Miccio focuses on Prostate Adenocarcinoma and Prostate Cancer. In particular, much of their work with Prostate Adenocarcinoma has involved Stage IV patients, or patients who are undergoing treatment.
Is Joseph A. Miccio currently recruiting for clinical trials?
Yes, Joseph A. Miccio is currently recruiting for 7 clinical trials in Hershey Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Joseph A. Miccio has studied deeply?
Yes, Joseph A. Miccio has studied treatments such as Apalutamide, Stereotactic Body Radiation Therapy, Relugolix.
What is the best way to schedule an appointment with Joseph A. Miccio?
Apply for one of the trials that Joseph A. Miccio is conducting.
What is the office address of Joseph A. Miccio?
The office of Joseph A. Miccio is located at: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania 17033-0850 United States. This is the address for their practice at the Penn State Milton S Hershey Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.